Sarepta’s Gene Therapy Under Scrutiny After Patient Death
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the "severity" of this case had not been seen before, the company noted. Elevidys has been used in more than 800 patients, the company stated.
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
StockStory.org on MSN1d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding TodayShares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback